GreatPoint Ventures led a $60m funding round in Excision BioTherapeutics.

GreatPoint Ventures, an early-stage venture capital investment firm, led a $60m funding round in Excision BioTherapeutics, a developer of potentially curative CRISPR anti-viral therapies to improve patient lives. "Over 38m people live with HIV and more than 250m live with Hepatitis B around the world. We are hopeful that Excision’s technology has the potential to eradicate these, as well as other diseases including PML and Herpes Virus," Vasudev Bailey, ARTIS Ventures Senior Partner.